Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia

Human Psychopharmacology
Naoki GotoJun Nakamura

Abstract

Schizophrenic patients demonstrate a variety of cognitive deficits, including attention, executive functions, and working memory, even in the early stage of disease. In the present study, we examined the association between blood levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), or brain-derived neurotrophic factor (BDNF) and scores on the Wisconsin Card Sorting Test (WCST) in patients with early-stage schizophrenia. We also investigated the association between frontal GABA levels using 1H-magnetic resonance spectroscopy (MRS) at 3T and scores on the WCST in the same patients. Blood levels of BDNF and catecholamine metabolites and brain GABA levels using 1H-MRS were measured in 18 schizophrenic patients (nine males, nine females; age range 13-52 year). A significantly positive correlation was observed between plasma MHPG levels and %PEM (rho = -0.686, p = 0.0047). A trend toward negative correlation was found between frontal lobe GABA levels and the per cent of preservation error (%PEM) in the early stage of schizophrenia (rho = -0.420, p = 0.0836). These results suggest that noradrenergic neurons might be involved in neuropsychological functions in early-stage of schizophrenia.

References

Jul 1, 1991·Archives of General Psychiatry·A J SaykinP Stafiniak
Feb 1, 1990·Archives of General Psychiatry·D L Braff, M A Geyer
Jun 1, 1986·International Journal of Sports Medicine·H Weicker
Jan 1, 1988·Schizophrenia Bulletin·T E Goldberg, D R Weinberger
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Apr 1, 1982·Journal of Clinical Psychology·M G Pendleton, R K Heaton
Dec 1, 1993·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·S W Provencher
Nov 5, 1998·NMR in Biomedicine·M MescherR Gruetter
Jul 20, 2002·Psychiatry Research·Kazuhiko ToyookaHiroyuki Nawa
Sep 26, 2002·The British Journal of Psychiatry. Supplement·S FriisT H McGlashan
Apr 2, 2003·Brain Research. Brain Research Reviews·Craig W Berridge, Barry D Waterhouse
Jul 24, 2003·Developmental Neuroscience·Z G RenM Sieber-Blum
Jul 28, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sebnem PirildarFisun Akdeniz
Apr 2, 2005·Nature Reviews. Neuroscience·David A LewisDavid W Volk
Mar 21, 2006·Journal of Psychiatric Research·Rodrigo W GrilloDiogo R Lara
Feb 20, 2007·Schizophrenia Research·Peter F BuckleySahebarao Mahadik
Sep 7, 2007·Journal of Neurophysiology·Saobo LeiHee-Sup Shin
May 30, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jason J RadleyPaul E Sawchenko
Apr 3, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Philip EckhoffPhilip Holmes
Apr 17, 2009·Biological Psychiatry·Sophia VinogradovSynthia H Mellon
Jun 24, 2009·Human Psychopharmacology·Wakako Umene-NakanoJun Nakamura

❮ Previous
Next ❯

Citations

Sep 13, 2012·European Archives of Psychiatry and Clinical Neuroscience·Nina PeselmannMathias Zink
Dec 3, 2014·Schizophrenia Research·Stephan F Taylor, Ivy F Tso
Dec 4, 2012·Neurobiology of Disease·Melis InanStewart A Anderson
Dec 14, 2011·Trends in Neurosciences·David A LewisDavid W Volk
Mar 9, 2017·International Journal of Molecular Sciences·Hikaru HoriHirotaka Tominaga
Jun 26, 2018·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Ulrike HeitzAnita Riecher-Rössler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.